Importer of Controlled Substances Application: Actavis Pharma, Inc., 32315-32316 [2014-12976]

Download as PDF Federal Register / Vol. 79, No. 107 / Wednesday, June 4, 2014 / Notices 2 The Title of the Form/Collection: Notice of Entry of Appearance as Attorney or Representative Before the Board of Immigration Appeals. 3 The agency form number, if any, and the applicable component of the Department sponsoring the collection: The form number is EOIR–27, Executive Office for Immigration Review, United States Department of Justice. 4 Affected public who will be asked or required to respond, as well as a brief abstract: Primary: Attorneys or representatives notifying the Board of Immigration Appeals (Board) that they are representing a party in proceedings before the Board. Other: None. Abstract: This information collection is necessary to allow an attorney or representative to notify the Board that he or she is representing a party before the Board. 5 An estimate of the total number of respondents and the amount of time estimated for an average respondent to respond: It is estimated that 26,544 respondents will complete the form annually with an average of 6 minutes per response. 6 An estimate of the total public burden (in hours) associated with the collection: The estimated public burden associated with this collection is 2,654 hours. It is estimated that respondents will take 6 minutes to complete the form. If additional information is required contact: Jerri Murray, Department Clearance Officer, United States Department of Justice, Justice Management Division, Policy and Planning Staff, Two Constitution Square, 145 N Street NE., 3E.405B, Washington, DC 20530. Dated: May 29, 2014. Jerri Murray, Department Clearance Officer for PRA, U.S. Department of Justice. [FR Doc. 2014–12835 Filed 6–3–14; 8:45 am] BILLING CODE 4410–30–P DEPARTMENT OF JUSTICE [OMB Number 1125–0006] tkelley on DSK3SPTVN1PROD with NOTICES Agency Information Collection Activities; Proposed eCollection eComments Requested; Notice of Entry of Appearance as Attorney or Representative Before the Immigration Court Overview of This information collection: Executive Office for Immigration Review, Department of Justice. ACTION: 60-Day notice. AGENCY: The Department of Justice (DOJ), Executive Office for Immigration SUMMARY: VerDate Mar<15>2010 16:05 Jun 03, 2014 Jkt 232001 Review (EOIR), will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995. The proposed information collection is published to obtain comments from the public and affected agencies. DATES: Comments are encouraged and will be accepted for 60 days until August 4, 2014. FOR FURTHER INFORMATION CONTACT: If you have comments, especially on the estimated public burden or associated response time, suggestions, or need a copy of the proposed information collection instrument with instructions or additional information, please contact Jeff Rosenblum, General Counsel, Executive Office for Immigration Review, U.S. Department of Justice, Suite 2600, 5107 Leesburg Pike, Falls Church, Virginia, 20530; telephone: (703) 305–0470. SUPPLEMENTARY INFORMATION: This process is conducted in accordance with 5 CFR 1320.10. Written comments and suggestions from the public and affected agencies concerning the proposed collection of information are encouraged. Your comments should address one or more of the following four points: —Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the Executive Office for Immigration Review, including whether the information will have practical utility; —Evaluate the accuracy of the agency’s estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; —Evaluate whether and if so how the quality, utility, and clarity of the information to be collected can be enhanced; and —Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submission of responses. PO 00000 Frm 00103 Fmt 4703 Sfmt 4703 Attorney or Representative Before the Immigration Court. 3 The agency form number, if any, and the applicable component of the Department sponsoring the collection: The form number is EOIR–28, Executive Office for Immigration Review, United States Department of Justice. 4 Affected public who will be asked or required to respond, as well as a brief abstract: Primary: Attorneys and qualified representatives notifying the Immigration Court that they are representing an alien in immigration proceedings. Other: None. Abstract: This information collection is necessary to allow an attorney or representative to notify the Immigration Court that he or she is representing an alien before the Immigration Court. 5 An estimate of the total number of respondents and the amount of time estimated for an average respondent to respond: It is estimated that 179,856 respondents will complete the form annually with an average of 6 minutes per response. 6 An estimate of the total public burden (in hours) associated with the collection: The estimated public burden associated with this collection is 17,985 hours. It is estimated that respondents will take six minutes to complete the form. If additional information is required contact: Jerri Murray, Department Clearance Officer, United States Department of Justice, Justice Management Division, Policy and Planning Staff, Two Constitution Square, 145 N Street NE., 3E.405B, Washington, DC 20530. Dated: May 29, 2014. Jerri Murray, Department Clearance Officer for PRA, U.S. Department of Justice. [FR Doc. 2014–12836 Filed 6–3–14; 8:45 am] BILLING CODE 4410–30–P DEPARTMENT OF JUSTICE Drug Enforcement Administration [Docket No. DEA–392] Importer of Controlled Substances Application: Actavis Pharma, Inc. ACTION: Notice of application. Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration in accordance with 21 CFR 1301.34(a) on or before July 7, 2014. Such persons DATES: 1 Type of Information Collection: Revision and extension of a currently approved collection. 2 The Title of the Form/Collection: Notice of Entry of Appearance as 32315 E:\FR\FM\04JNN1.SGM 04JNN1 32316 Federal Register / Vol. 79, No. 107 / Wednesday, June 4, 2014 / Notices may also file a written request for a hearing on the application pursuant to 21 CFR 1301.43 on or before July 7, 2014. DEPARTMENT OF JUSTICE appropriate. 72 FR 3417 (January 25, 2007). Drug Enforcement Administration [Docket No. DEA–392] Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/ODW, 8701 Morrissette Drive, Springfield, Virginia 22152. Importer of Controlled Substances Application: Penick Corporation Dated: May 28, 2014. Joseph T. Rannazzisi, Deputy Assistant Administrator. [FR Doc. 2014–12962 Filed 6–3–14; 8:45 am] ADDRESSES: The Attorney General has delegated his authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, and dispensers of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Deputy Assistant Administrator of the DEA Office of Diversion Control (‘‘Deputy Assistant Administrator’’) pursuant to sec. 7(g) of 28 CFR part 0, subpart R, App. In accordance with 21 CFR 1301.34(a), this is notice that on March 20, 2014, Actavis Pharma, Inc., 2455 Wardlow Road, Corona, California 92880–2882, applied to be registered as an importer of the following basic classes of controlled substances: SUPPLEMENTARY INFORMATION: Controlled substance Schedule Amphetamine (1100) .................... Methylphenidate (1724) ................ Oxycodone (9143) ........................ Hydromorphone (9150) ................ II II II II tkelley on DSK3SPTVN1PROD with NOTICES The company plans to import the listed controlled substances for analytical testing and clinical trials. The import of the above listed basic classes of controlled substances will be granted only for analytical testing and clinical trials. This authorization does not extend to the import of a finished Food and Drug Administration approved or non-approved dosage form for commercial distribution in the United States. Dated: May 28, 2014. Joseph T. Rannazzisi, Deputy Assistant Administrator. [FR Doc. 2014–12976 Filed 6–3–14; 8:45 am] BILLING CODE 4410–09–P VerDate Mar<15>2010 16:05 Jun 03, 2014 Jkt 232001 ACTION: Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration in accordance with 21 CFR 1301.34(a) on or before July 7, 2014. Such persons may also file a written request for a hearing on the application pursuant to 21 CFR 1301.43 on or before July 7, 2014. DATES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/ODW, 8701 Morrissette Drive, Springfield, Virginia 22152. ADDRESSES: The Attorney General has delegated his authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, and dispensers of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Deputy Assistant Administrator of the DEA Office of Diversion Control (‘‘Deputy Assistant Administrator’’) pursuant to sec. 7(g) of 28 CFR part 0, subpart R, App. In accordance with 21 CFR 1301.34(a), this is notice that on February 26, 2014, Penick Corporation, 33 Industrial Park Road, Pennsville, New Jersey 08070, applied to be registered as an importer of the following basic classes of controlled substances: SUPPLEMENTARY INFORMATION: Controlled substance Opium, raw (9600) ....................... Poppy Straw Concentrate (9670) Schedule II II The company plans to import the listed controlled substances to manufacture bulk controlled substance intermediates for sale to its customers. Comments and requests for any hearings on applications to import narcotic raw material are not PO 00000 BILLING CODE 4410–09–P Notice of application. Frm 00104 Fmt 4703 Sfmt 4703 DEPARTMENT OF JUSTICE Drug Enforcement Administration [Docket No. DEA–392] Importer of Controlled Substances Application: Mylan Technologies, Inc. ACTION: Notice of application. Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration in accordance with 21 CFR 1301.34(a) on or before July 7, 2014. Such persons may also file a written request for a hearing on the application pursuant to 21 CFR 1301.43 on or before July 7, 2014. ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/ODW, 8701 Morrissette Drive, Springfield, Virginia 22152. SUPPLEMENTARY INFORMATION: The Attorney General has delegated his authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, and dispensers of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Deputy Assistant Administrator of the DEA Office of Diversion Control (‘‘Deputy Assistant Administrator’’) pursuant to sec. 7(g) of 28 CFR pt. 0, subpt. R, App. In accordance with 21 CFR 1301.34(a), this is notice that on December 12, 2013, Mylan Technologies, Inc., 110 Lake Street, Saint Albans, Vermont 05478, applied to be registered as an importer of the following basic classes of controlled substances: DATES: Controlled Substance Methylphenidate (1724) ................ E:\FR\FM\04JNN1.SGM 04JNN1 Schedule II

Agencies

[Federal Register Volume 79, Number 107 (Wednesday, June 4, 2014)]
[Notices]
[Pages 32315-32316]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-12976]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-392]


Importer of Controlled Substances Application: Actavis Pharma, 
Inc.

ACTION: Notice of application.

-----------------------------------------------------------------------

DATES: Registered bulk manufacturers of the affected basic classes, and 
applicants therefore, may file written comments on or objections to the 
issuance of the proposed registration in accordance with 21 CFR 
1301.34(a) on or before July 7, 2014. Such persons

[[Page 32316]]

may also file a written request for a hearing on the application 
pursuant to 21 CFR 1301.43 on or before July 7, 2014.

ADDRESSES: Written comments should be sent to: Drug Enforcement 
Administration, Attention: DEA Federal Register Representative/ODW, 
8701 Morrissette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: The Attorney General has delegated his 
authority under the Controlled Substances Act to the Administrator of 
the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority 
to exercise all necessary functions with respect to the promulgation 
and implementation of 21 CFR part 1301, incident to the registration of 
manufacturers, distributors, and dispensers of controlled substances 
(other than final orders in connection with suspension, denial, or 
revocation of registration) has been redelegated to the Deputy 
Assistant Administrator of the DEA Office of Diversion Control 
(``Deputy Assistant Administrator'') pursuant to sec. 7(g) of 28 CFR 
part 0, subpart R, App.
    In accordance with 21 CFR 1301.34(a), this is notice that on March 
20, 2014, Actavis Pharma, Inc., 2455 Wardlow Road, Corona, California 
92880-2882, applied to be registered as an importer of the following 
basic classes of controlled substances:

------------------------------------------------------------------------
            Controlled substance                       Schedule
------------------------------------------------------------------------
Amphetamine (1100).........................  II
Methylphenidate (1724).....................  II
Oxycodone (9143)...........................  II
Hydromorphone (9150).......................  II
------------------------------------------------------------------------

    The company plans to import the listed controlled substances for 
analytical testing and clinical trials.
    The import of the above listed basic classes of controlled 
substances will be granted only for analytical testing and clinical 
trials. This authorization does not extend to the import of a finished 
Food and Drug Administration approved or non-approved dosage form for 
commercial distribution in the United States.

    Dated: May 28, 2014.
Joseph T. Rannazzisi,
Deputy Assistant Administrator.
[FR Doc. 2014-12976 Filed 6-3-14; 8:45 am]
BILLING CODE 4410-09-P